Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada

Background: Biophasic insulin aspart (InAsBi) is a mixture of 30% of rapid acting soluble aspart insulin and 70% aspart insulin retarded with protamine. The soluble portion reduces postprandial serum glucose rises and the retarded portion reduces basal glucose levels. Aim: To assess the efficacy of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	García de los Ríos,Manuel, Wolff,Carlos, Duarte,Erika
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2007
Materias:	Diabetes mellitus Hemoglobins Insulin, aspartic acid (B28)
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001000004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872007001000004
record_format	dspace
spelling	oai:scielo:S0034-988720070010000042007-12-20Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programadaGarcía de los Ríos,ManuelWolff,CarlosDuarte,Erika Diabetes mellitus Hemoglobins Insulin, aspartic acid (B28) Background: Biophasic insulin aspart (InAsBi) is a mixture of 30% of rapid acting soluble aspart insulin and 70% aspart insulin retarded with protamine. The soluble portion reduces postprandial serum glucose rises and the retarded portion reduces basal glucose levels. Aim: To assess the efficacy of biphasic insulin aspart in diabetics with a bad metabolic control. Material and methods: Multicentríc study that included diabetic patients with a glycosilated hemoglobin over 7% that were transferred to treatment with InAsBi, given in one to three daily doses, according to glycemic control and followed for 12 weeks. At the end of follow up, glycosilated hemoglobin levels (HbA1c) were measured again. Results: One hundred ninety six patients were enrolled and 154, age 59± 12 (84 females), completed the follow up. HbA 1 c levels decreased in at ¡east 1% in 96 and increased in eight cases. In the total group HbA1c decreased from 10.1± 1.7 to 8.4±1.4% (p <0.01). Those with higher initial values and with oral therapy, had the greatest reductions. At the end of the observation period, 29 patients received one daily dose of InAsBi, 114 two doses and 11 three doses. Two patients had allergy, one systemic and one in the injection site. Conclusions: In this group of diabetic patients with a bad metabolic control, the use of InAsBi was associated with a significant reduction of glycosilated hemoglobin levelsinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.135 n.10 20072007-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001000004es10.4067/S0034-98872007001000004
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Diabetes mellitus Hemoglobins Insulin, aspartic acid (B28)
spellingShingle	Diabetes mellitus Hemoglobins Insulin, aspartic acid (B28) García de los Ríos,Manuel Wolff,Carlos Duarte,Erika Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada
description	Background: Biophasic insulin aspart (InAsBi) is a mixture of 30% of rapid acting soluble aspart insulin and 70% aspart insulin retarded with protamine. The soluble portion reduces postprandial serum glucose rises and the retarded portion reduces basal glucose levels. Aim: To assess the efficacy of biphasic insulin aspart in diabetics with a bad metabolic control. Material and methods: Multicentríc study that included diabetic patients with a glycosilated hemoglobin over 7% that were transferred to treatment with InAsBi, given in one to three daily doses, according to glycemic control and followed for 12 weeks. At the end of follow up, glycosilated hemoglobin levels (HbA1c) were measured again. Results: One hundred ninety six patients were enrolled and 154, age 59± 12 (84 females), completed the follow up. HbA 1 c levels decreased in at ¡east 1% in 96 and increased in eight cases. In the total group HbA1c decreased from 10.1± 1.7 to 8.4±1.4% (p <0.01). Those with higher initial values and with oral therapy, had the greatest reductions. At the end of the observation period, 29 patients received one daily dose of InAsBi, 114 two doses and 11 three doses. Two patients had allergy, one systemic and one in the injection site. Conclusions: In this group of diabetic patients with a bad metabolic control, the use of InAsBi was associated with a significant reduction of glycosilated hemoglobin levels
author	García de los Ríos,Manuel Wolff,Carlos Duarte,Erika
author_facet	García de los Ríos,Manuel Wolff,Carlos Duarte,Erika
author_sort	García de los Ríos,Manuel
title	Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada
title_short	Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada
title_full	Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada
title_fullStr	Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada
title_full_unstemmed	Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada
title_sort	tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: experiencia clínica programada
publisher	Sociedad Médica de Santiago
publishDate	2007
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001000004
work_keys_str_mv	AT garciadelosriosmanuel tratamientoconinsulinaasparticabifasicaenpacientescondiabetesenmalcontrolmetabolicoexperienciaclinicaprogramada AT wolffcarlos tratamientoconinsulinaasparticabifasicaenpacientescondiabetesenmalcontrolmetabolicoexperienciaclinicaprogramada AT duarteerika tratamientoconinsulinaasparticabifasicaenpacientescondiabetesenmalcontrolmetabolicoexperienciaclinicaprogramada
_version_	1718436343209525248

Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico: Experiencia clínica programada

Ejemplares similares